A single platform that can both quantify and characterize cancer to accelerate insights from research to clinical practice.
The first FDA-approved comprehensive liquid biopsy for all advanced solid tumors, available in 60+ countries.1-3
A single platform that can both quantify and characterize cancer to accelerate insights from research to clinical practice.
References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 2. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Updated August 11, 2020. Accessed April 2, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 3. Guardant Health data on file. Guardant Health, Inc. Redwood City, CA.
The first FDA-approved comprehensive liquid biopsy for all advanced solid tumors, available in 60+ countries.1-3
